
The study explores ocular adverse events (OAE) in atopic dermatitis (AD) patients treated with dupilumab. Researchers analyzed conjunctival cells from 36 patients before (M0) and 4 months after (M4) treatment, categorizing them into those with OAE (OAE+) and without (OAE-). At M0, 52 differentially expressed genes (DEGs) were identified, increasing to 113 at M4. OAE+ patients exhibited a psoriasis signature and upregulated genes linked to keratinocyte differentiation. Validation confirmed 9 DEGs, suggesting that certain transcriptomic profiles may predispose AD patients to develop OAE during dupilumab treatment.
Like
Save
Share